Signed in
We value your privacy
This site uses cookies to improve your browsing experience, analyze site traffic, and show personalized content.
| $0.850.03% | |
| $0.000.00% | |
| $0.000.00% | |
| $0.000.00% | |
| $0.000.00% | |
| $0.000.00% | |
| $0.000.00% |
Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that it has received IND clearance from FDA for ISM5939, a potential best-in-class oral small molecule inhibitor targeting ENPP1 for the treatment of solid tumors.